<DOC>
	<DOC>NCT02850406</DOC>
	<brief_summary>This study consists of two parts, Part A and Part B. Part A is a single dose PK study in adolescent subjects with Sickle Cell Disease. Part B is a multiple dose safety, exploratory efficacy and PK study in adolescent Sickle Cell Disease subjects.</brief_summary>
	<brief_title>Study to Evaluate the Effect of GBT440 in Adolescents With Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<criteria>1. Male or female age 12 to 17 years of age (inclusive) with homozygous hemoglobin SS (HbSS) or hemoglobin S beta0 thalassemia (HbS β0 thal). 2. A subject taking hydroxyurea may be enrolled if the dose has been stable for at least 3 months with no anticipated need for dose adjustments during the study and no sign of hematological toxicity. 3. Written informed parental/ guardian consent and subject assent has been obtained per institutional review board (IRB)/Ethics Committee (EC) policy and requirements, consistent with International Council on Harmonisation (ICH) guidelines. 1. Any one of the following requiring medical attention within 14 days prior to signing the informed consent form (ICF): Vasoocclusive crisis (VOC) Acute chest syndrome (ACS) Stroke Splenic sequestration crisis Dactylitis 2. Requires chronic transfusion therapy 3. History of stroke or meeting criteria for primary stroke prophylaxis (history of two Transcranial Doppler (TCD) measurements ≥ 200 cm/sec) 4. Transfusion within 30 days prior to signing the Informed Consent Form. 5. Renal dysfunction requiring chronic dialysis or creatinine ≥ 1.5 milligrams per deciliter (mg/dL) 6. History of hepatic compromise or severe liver disease 7. Clinically relevant cardiac abnormality</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>